The Zacks Analyst Blog Highlights: Alcoa, J.P. Morgan, Wells Fargo, Integra LifeSciences Holdings and Covidien

News provided by

Apr 08, 2014, 09:30 ET

CHICAGO, April 8, 2014 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Alcoa (NYSE:AA-Free Report), J.P. Morgan (NYSE:JPM-Free Report), Wells Fargo (NYSE:WFC-Free Report), Integra LifeSciences Holdings Corporation (Nasdaq:IART-Free Report) and Covidien plc (NYSE:COV-Free Report).

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Monday's Analyst Blog:

Will Earnings Be the Catalyst?

The 2014 Q1 earnings season will get in the spotlight with Tuesday's Alcoa (NYSE:AA-Free Report) release and Friday's reports by J.P. Morgan (NYSE:JPM-Free Report) and Wells Fargo (NYSE:WFC-Free Report).

Expectations for Q1 remain low, having fallen sharply under the weight of overwhelmingly negative guidance from management teams. Total earnings for companies in the S&P 500 are expected to be down -3.3% from the same period last year on modestly higher revenues and lower margins. This is the second time since the current cycle got underway in 2009 that earnings for the S&P 500 index are expected to be down at this stage.

Negative revisions have been a persistent trend for more than a year now, though the magnitude of negative revisions to Q1 estimates was greater than what we have witnessed in other recent quarters. Weather was likely a big reason for the increased Q1 estimate cuts, with retail and other weather exposed sectors suffering heavy revisions. But the overall Q1 weakness is broad-based and not concentrated in any one sector – 10 of the 16 Zacks sectors are currently expected to show earnings declines in the quarter.

The flip side of low estimates is that it provides an easy hurdle rate for companies to jump through. Roughly two-thirds of the S&P 500 members come out with positive earnings surprises in any given quarter and if Q1 estimates really are on the low side, then beat ratios could very well come out on the higher side this time around. But more than positive earnings (and revenue) surprises, the market will be looking for some evidence that the outlook for the coming quarters is stabilizing, if not improving.

The current consensus earnings view puts Q1 as the low point for the year, both in terms of growth as well as the overall level of total earnings. But the expectation is of notable improvement from Q2 onwards and a strong ramp-up later this year and into 2015. Guidance will determine how the outlook for those coming quarters will evolve. Guidance has been negative for more than a year now and estimates for Q2 and beyond will start coming down if we don't see any change on that front in the next few weeks.

The economic reports for March, including Friday's jobs report, have broadly confirmed that the U.S. economy has started to come out of the Winter freeze. The magnitude and pace of the bounce-back in activity levels has been a bit on the weak side, but there is notable improvement in March data relative to what we saw in the first two months of the year. Investors will be looking for a similar trend on the earnings side as well.

FDA OKs New Integra Catheter

Leading medical technology company – Integra LifeSciences Holdings Corporation (Nasdaq:IART-Free Report) gained the U.S. Food and Drug Administration (FDA) approval for its Camino Flex Ventricular Catheter for use with magnetic resonance imaging (MRI). The Camino Flex Ventricular Catheter is used in conjunction with Integra's next-generation Camino Monitor.

According to Integra, Camino Flex is a tunneled ventricular catheter and is MR conditional at 1.5 and 3.0 T. The product clearly has a clinical advantage over other tunneled ventricular catheters as it is capable of consistently monitoring intracranial pressure (ICP) independently in the ventricles.

The Camino Flex Ventricular Catheter, when used along with the Camino Monitor, equips healthcare providers with a highly advanced and innovative technology to efficiently diagnose and treat complex and compromised neurological conditions. With the increasing demand of MRI for patients undergoing neuromonitoring and with approximately 800 centers in the U.S. using the Camino platform, we believe, this FDA approval will strengthen the foothold of Integra in the market for neurological and neurosurgical devices.

The Camino Flex Ventricular Catheter falls under the company's U.S. Neurosurgery business segment, which contributed 20.6% of total revenues in 2013. In a bid to enhance its product offerings under this segment, Integra acquired the DuraSeal product lines from Covidien plc (NYSE:COV-Free Report) in Jan 2014. We believe Integra is steadily executing its strategy of accelerated growth through its near-term objectives like portfolio optimization and strategic corporate development.

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.

Get the full Report on AA - FREE
Get the full Report on JPM - FREE
Get the full Report on WFC - FREE
Get the full Report on IART - FREE
Get the full Report on COV - FREE

Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
[email protected]
http://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Logo - http://photos.prnewswire.com/prnh/20101027/ZIRLOGO

SOURCE Zacks Investment Research, Inc.